Clinical trial
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
NCT00449280 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00449280 |
|---|---|
| Title | Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies |
| Official title | A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumor |
| Intervention type | Drug |
| Interventions | Sorafenib, Rapamycin |
| Enrollment | 34 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Mar 20, 2007 |
| Last update posted | Jun 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: